Get the Stockscreener App
7.68
1.41%
-0.11
Pre-market:
7.39
-0.29
-3.78%
Nyxoah Sa stock is traded at $7.68, with a volume of 12,253.
It is down -1.41% in the last 24 hours and down -0.78% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$7.79
Open:
$7.7
24h Volume:
12,253
Relative Volume:
0.08
Market Cap:
$290.08M
Revenue:
$4.71M
Net Income/Loss:
$-46.77M
P/E Ratio:
-4.5736
EPS:
-1.6792
Net Cash Flow:
$-60.34M
1W Performance:
-0.52%
1M Performance:
-0.78%
6M Performance:
-4.00%
1Y Performance:
+11.79%
1-Day Range:
$7.62
$7.71
1-Week Range:
$7.555
$8.02
52-Week Range:
$5.55
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
7.68 | 290.08M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
534.19 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
169.97 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.11 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
256.21 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
219.00 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
(NYXH) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 2, 2025 - Yahoo Finance
Major Governance Shift: Nyxoah Grants Long-term Shareholders New Board Nomination Rights - Stock Titan
Cantor Fitzgerald Forecasts Nyxoah FY2026 Earnings - Defense World
Ameriprise Financial Inc. Takes $135,000 Position in Nyxoah S.A. (NASDAQ:NYXH) - Defense World
When the Price of (NYXH) Talks, People Listen - news.stocktradersdaily.com
Top Premarket Decliners - marketscreener.com
Millennium Management LLC Trims Stock Holdings in Nyxoah S.A. (NASDAQ:NYXH) - Defense World
Nyxoah Announces Change in Shareholder Voting Rights - TipRanks
Vestal Point Capital Cuts Nyxoah Holdings by 40%: Major Ownership Shift Revealed - Stock Titan
Nyxoah to Present at the Jefferies Global Healthcare Conference - The Manila Times
Nyxoah CEO Showcases Revolutionary Sleep Apnea Treatment at Major Jefferies Healthcare Conference - Stock Titan
Nyxoah SA Updates Share Capital and Voting Rights - TipRanks
Information on the total number of voting rights and shares - Yahoo
Head-To-Head Survey: Inspire Medical Systems (NYSE:INSP) versus Nyxoah (NASDAQ:NYXH) - Defense World
Cantor maintains Nyxoah stock Overweight with $14 target By Investing.com - Investing.com Nigeria
Nyxoah Announces CE Mark Approval For Genio® 2.1 - Barchart.com
Cantor maintains Nyxoah stock Overweight with $14 target - Investing.com
Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates - MSN
Trading (NYXH) With Integrated Risk Controls - news.stocktradersdaily.com
Nyxoah Sa’s Earnings Call: Progress Amid Challenges - TipRanks
Nyxoah outlines U.S. Genio launch plan with 50-member team as FDA approval expected Q2 2025 - MSN
Nyxoah S.A. (NASDAQ:NYXH) Q1 2025 Earnings Call Transcript - Insider Monkey
Nyxoah Reports Q1 2025 Financial Results and FDA Progress - TipRanks
Nyxoah Q1 2025 Earnings Call Transcript - MarketBeat
Nyxoah Nears FDA Approval for Genio® System Amid Q1 2025 Results - TipRanks
Nyxoah (NYXH) Nears FDA Approval for Genio System in the U.S. | - GuruFocus
Nyxoah reports Q1 EPS (EUR 0.60) vs. (EUR 0.42) last year - TipRanks
Nyxoah Reports First Quarter Financial and Operating Results - The Manila Times
Nyxoah Nears FDA Approval for Sleep Apnea Device as Q1 Revenue Hits €1.1M | NYXH Stock News - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. – NYXH - Bluefield Daily Telegraph
Earnings To Watch: Nyxoah SA (NYXH) Reports Q1 2025 Result - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A.NYXH - PR Newswire
Nyxoah (NYXH) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Publication relating to transparency notifications - Stock Titan
Nyxoah SA Schedules Shareholders’ Meetings for June 2025 - TipRanks
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 11, 2025 - Yahoo Finance
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 - The Manila Times
REG-Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 - TradingView
Renaissance Technologies LLC Purchases Shares of 23,400 Nyxoah S.A. (NASDAQ:NYXH) - Defense World
Long Term Trading Analysis for (NYXH) - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A.NYXH - Bluefield Daily Telegraph
Nyxoah S.A. (NASDAQ:NYXH) Shares Bought by Geode Capital Management LLC - Defense World
LPL Financial LLC Buys Shares of 12,700 Nyxoah S.A. (NASDAQ:NYXH) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Stifel cuts Nyxoah stock price target to $14, maintains Buy rating - Investing.com Canada
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):